Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,549 JPY | -0.57% | -0.88% | -18.28% |
May. 24 | Japan companies hog the spotlight as hedge funds tout their top Asia picks | RE |
Mar. 31 | A second Kobayashi Pharma Japan factory inspected over deaths | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 22.99 times its 2024 earnings per share.
- The company is highly valued given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.28% | 2.64B | C+ | ||
+14.29% | 395B | C- | ||
+14.66% | 139B | B- | ||
+17.88% | 77.04B | A+ | ||
-4.06% | 72.13B | A- | ||
-19.59% | 42.6B | B+ | ||
-14.21% | 35.02B | - | ||
+12.16% | 18.64B | A- | ||
+26.34% | 17.42B | B | ||
+10.10% | 13.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4967 Stock
- Ratings Kobayashi Pharmaceutical Co., Ltd.